The role of mTOR inhibitors for the treatment of B-cell lymphomas

Advances in Hematology

Volumn 2012, Issue , 2012, Pages

  Argyriou, Pinelopi ^a   Economopoulou, Panagiota ^b   Papageorgiou, Sotirios ^b,c  

^a EVANGELISMOS HOSPITAL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; AZD 8055; EVEROLIMUS; KU 0063794; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PP 42; PROTEIN KINASE B; RAF PROTEIN; RAPALOG; RAPAMYCIN; RIDAFOROLIMUS; RITUXIMAB; TEMSIROLIMUS; TORIN 1; UNCLASSIFIED DRUG; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; ASTHENIA; B CELL LYMPHOMA; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DIARRHEA; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ENZYME ACTIVATION; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MOUTH DISEASE; MOUTH SORE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMATITIS; THROMBOCYTOPENIA;

EID: 80052774270     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2012/435342     Document Type: Review

References (127)

1. Johnston P. B., Yuan R., Cavalli F., Witzig T. E., Targeted therapy in lymphoma Journal of Hematology Oncology 2010 3 45
2. Vu C., Fruman D. A., Target of rapamycin signaling in leukemia and lymphoma Clinical Cancer Research 2010 16 5374 5380
3. Ma W. W., Adjei A. A., Novel agents on the horizon for cancer therapy CA: Cancer Journal for Clinicians 2009 59 2 111 137
4. Wullschleger S., Loewith R., Hall M. N., TOR signaling in growth and metabolism Cell 2006 124 3 471 484 (Pubitemid 43199434)
5. Soliman G. A., The mammalian target of rapamycin signalling network and gene regulation Current Opinion in Lipidology 2005 16 3 317 323 (Pubitemid 40839761)
6. Inoki K., Ouyang H., Li Y., Guan K. L., Signaling by target of rapamycin proteins in cell growth control Microbiology and Molecular Biology Reviews 2005 69 1 79 100 (Pubitemid 40358068)
7. Foster K. G., Fingar D. C., Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony Journal of Biological Chemistry 2010 285 19 14071 14077
8. Peterson T. R., Laplante M., Thoreen C. C., Sancak Y., Kang S. A., Kuehl W. M., Gray N. S., Sabatini D. M., DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival Cell 2009 137 5 873 886
9. Menon S., Manning B. D., Common corruption of the mTOR signaling network in human tumors Oncogene 2008 27 supplement 2 S43 S51
10. Huang J., Manning B. D., The TSC1-TSC2 complex: a molecular switchboard controlling cell growth Biochemical Journal 2008 412 2 179 190 (Pubitemid 351758225)
11. Memmott R. M., Dennis P. A., Akt-dependent and -independent mechanisms of mTOR regulation in cancer Cellular Signalling 2009 21 5 656 664
12. McCubrey J. A., Steelman L. S., Chappell W. H., Abrams S. L., Wong E. W. T., Chang F., Lehmann B., Terrian D. M., Milella M., Tafuri A., Stivala F., Libra M., Basecke J., Evangelisti C., Martelli A. M., Franklin R. A., Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance Biochimica et Biophysica Acta 2007 1773 8 1263 1284 (Pubitemid 47125967)
13. Cully M., Genevet A., Warne P., Treins C., Liu T., Bastien J., Baum B., Tapon N., Leevers S. J., Downward J., A role for p38 stress-activated protein kinase in regulation of cell growth via TORC1 Molecular and Cellular Biology 2010 30 2 481 495
14. Ballou L. M., Lin R. Z., Rapamycin and mTOR kinase inhibitors Journal of Chemical Biology 2008 1 27 36
15. Cybulski N., Hall M. N., TOR complex 2: a signaling pathway of its own Trends in Biochemical Sciences 2009 34 12 620 627
16. Tato I., Bartrons R., Ventura F., Rosa J. L., Amino acids activate mTOR complex 2 via PI3K/Akt signalling Journal of Biological Chemistry 2011 286 8 6128 6142
17. Choo A. Y., Blenis J., Not all substrates are treated equally Implications for mTOR, rapamycin-resistance and cancer therapy Cell Cycle 2009 8 4 567 572
18. Sun Q., Chen X., Ma J., Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth Proceedings of the National Academy of Sciences 2011 108 4129 4134
19. Alessi D. R., Pearce L. R., Garca-Martnez J. M., New insights into mTOR signaling: mTORC2 and beyond Science Signaling 2009 2 67 pe27
20. Li W., Petrimpol M., Molle K. D., Hall M. N., Battegay E. J., Humar R., Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2 Circulation Research 2007 100 1 79 87 (Pubitemid 46066776)
21. Zhang F., Zhang X., Li M., mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis Cancer Research 2010 70 9360 9370
22. Dutton A., Reynolds G. M., Dawson C. W., Young L. S., Murray P. G., Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR Journal of Pathology 2005 205 4 498 506 (Pubitemid 40361339)
23. Brown R. E., Kamal N. R., p-p70S6K (Thr 389) expression in nodular sclerosing Hodgkin's disease as evidence for receptor tyrosine kinase signaling Annals of Clinical and Laboratory Science 2005 35 4 413 414 (Pubitemid 41579571)
24. El-Salem M., Raghunath P. N., Marzec M., Liu X., Kasprzycka M., Robertson E., Wasik M. A., Activation of mTORC1 signaling pathway in AIDS-related lymphomas American Journal of Pathology 2009 175 2 817 824
25. De J., Brown R. E., Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma International Journal of Clinical and Experimental Medicine 2010 3 1 55 68
26. Zheng B., Flumara P., Li Y. V., Georgakis G., Snell V., Younes M., Vauthey J. N., Carbone A., Younes A., MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival Blood 2003 102 3 1019 1027 (Pubitemid 36917799)
27. Peponi E., Drakos E., Reyes G., Leventaki V., Rassidakis G. Z., Medeiros L. J., Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma American Journal of Pathology 2006 169 6 2171 2180 (Pubitemid 351181976)
28. Rudelius M., Pittaluga S., Nishizuka S., Pham T. H. T., Fend F., Jaffe E. S., Quintanilla-Martinez L., Raffeld M., Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma Blood 2006 108 5 1668 1676 (Pubitemid 44316136)
29. Psyrri A., Papageorgiou S., Liakata E., Scorilas A., Rontogianni D., Kontos C. K., Argyriou P., Pectasides D., Harhalakis N., Pappa V., Kolialexi A., Economopoulou C., Kontsioti F., Maratou E., Dimitriadis G., Economopoulou P., Economopoulos T., Phosphatidylinositol 3′-kinase catalytic subunit gene amplification contributes to the pathogenesis of mantle cell lymphoma Clinical Cancer Research 2009 15 18 5724 5732
30. Argyriou P., Papageorgiou S. G., Panteleon V., Hypoxia-inducible factors in mantle cell lymphoma: implication for an activated mTORC1→HIF-1 pathway Annals of Hematology 2011 90 315 322
31. Dennison J. B., Shanmugam M., Ayres M. L., 8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma Blood 2010 116 5622 5630
32. Yu B. H., Zhou X. Y., Xiao X. Y., Yan S. Y., Qin T., Shi D. R., Activation and clinicopathologic significance of AKT/mTOR signaling pathway in diffuse large B-cell lymphoma Chinese Journal of Pathology 2009 38 1 35 41
33. Zhao M. Y., Auerbach A., D'Costa A. M., Rapoport A. P., Burger A. M., Sausville E. A., Stass S. A., Jiang F., Sands A. M., Aguilera N., Zhao X. F., Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy Clinical Cancer Research 2009 15 5 1708 1720
34. Baohua Y., Xiaoyan Z., Tiecheng Z., Tao Q., Daren S., Mutations of the PIK3CA gene in diffuse large B cell lymphoma Diagnostic Molecular Pathology 2008 17 3 159 165
35. Abubaker J., Bavi P. P., Al-Harbi S., Siraj A. K., Al-Dayel F., Uddin S., Al-Kuraya K., PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma Leukemia 2007 21 11 2368 2370 (Pubitemid 350011714)
36. Uddin S., Bu R., Ahmed M., Hussain A. R., Ajarim D., Al-Dayel F., Bavi P., Al-Kuraya K. S., Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma Leukemia and Lymphoma 2010 51 7 1305 1314
37. Kuo S. H., Yeh P. Y., Chen L. T., Wu M. S., Lin C. W., Yeh K. H., Tzeng Y. S., Chen J. Y., Hsu P. N., Lin J. T., Cheng A. L., Overexpression of B cell activating factor of TNF family (BAFF) is associated with Helicobacter pylori independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma Blood 2008 112 7 2927 2934
38. Tjin E. P. M., Groen R. W. J., Vogelzang I., Derksen P. W. B., Klok M. D., Meijer H. P., Van Eeden S., Pals S. T., Spaargaren M., Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma Blood 2006 107 2 760 768 (Pubitemid 43076403)
39. Davis R. E., Ngo V. N., Lenz G., Tolar P., Young R. M., Romesser P. B., Kohlhammer H., Lamy L., Zhao H., Yang Y., Xu W., Shaffer A. L., Wright G., Xiao W., Powell J., Jiang J. K., Thomas C. J., Rosenwald A., Ott G., Muller-Hermelink H. K., Gascoyne R. D., Connors J. M., Johnson N. A., Rimsza L. M., Campo E., Jaffe E. S., Wilson W. H., Delabie J., Smeland E. B., Fisher R. I., Braziel R. M., Tubbs R. R., Cook J. R., Weisenburger D. D., Chan W. C., Pierce S. K., Staudt L. M., Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma Nature 2010 463 7277 88 92
40. Leseux L., Hamdi S. M., Al Saati T., Capilla F., Recher C., Laurent G., Bezombes C., Syk-dependent mTOR activation in follicular lymphoma cells Blood 2006 108 13 4156 4162 (Pubitemid 44913287)
41. Gupta M., Dillon S. R., Ziesmer S. C., Feldman A. L., Witzig T. E., Ansell S. M., Cerhan J. R., Novak A. J., A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation Blood 2009 113 21 5206 5216
42. Leseux L., Laurent G., Laurent C., Rigo M., Blanc A., Olive D., Bezombes C., PKC -mTOR pathway: a new target for rituximab therapy in follicular lymphoma Blood 2008 111 1 285 291
43. Zha H., Raffeld M., Charboneau L., Pittaluga S., Kwak L. W., Petricoin E., Liotta L. A., Jaffe E. S., Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray Laboratory Investigation 2004 84 2 235 244 (Pubitemid 41656505)
44. Gulmann C., Espina V., Petricoin E. III, Longo D. L., Santi M., Knutsen T., Raffeld M., Jaffe E. S., Liotta L. A., Feldman A. L., Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma Clinical Cancer Research 2005 11 16 5847 5855 (Pubitemid 41170312)
45. Calvo K. R., Dabir B., Kovach A., Devor C., Bandle R., Bond A., Shih J. H., Jaffe E. S., IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma Blood 2008 112 9 3818 3826
46. Wlodarski P., Kasprzycka M., Liu X., Marzec M., Robertson E. S., Slupianek A., Wasik M. A., Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-1, and serum Cancer Research 2005 65 17 7800 7808 (Pubitemid 41297255)
47. Sin S. H., Roy D., Wang L., Staudt M. R., Fakhari F. D., Patel D. D., Henry D., Harrington W. J., Damania B. A., Dittmer D. P., Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling Blood 2007 109 5 2165 2173 (Pubitemid 46348219)
48. Bhatt A. P., Bhende P. M., Sin S. H., Roy D., Dittmer D. P., Damania B., Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas Blood 2010 115 22 4455 4463
49. Col J. D., Zancai P., Terrin L., Guidoboni M., Ponzoni M., Pavan A., Spina M., Bergamin S., Rizzo S., Tirelli U., De Rossi A., Doglioni C., Dolcetti R., Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma Blood 2008 111 10 5142 5151
50. Lu X., Nechushtan H., Ding F., Rosado M. F., Singal R., Alizadeh A. A., Lossos I. S., Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas Blood 2005 105 7 2924 2932 (Pubitemid 40446287)
51. Renné C., Willenbrock K., Martin-Subero J. I., Hinsch N., Dring C., Tiacci E., Klapper W., Mller P., Kppers R., Hansmann M. L., Siebert R., Bruninger A., High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma Leukemia 2007 21 4 780 787 (Pubitemid 46444563)
52. Tauzin S., Ding H., Burdevet D., Borisch B., Hoessli D. C., Membrane-associated signaling in human B-lymphoma lines Experimental Cell Research 2011 317 151 162
53. Portis T., Longnecker R., Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway Oncogene 2004 23 53 8619 8628 (Pubitemid 39576469)
54. Swart R., Ruf I. K., Sample J., Longnecker R., Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-kinase/Akt pathway Journal of Virology 2000 74 22 10838 10845
55. Tomlinson C. C., Damania B., The K1 protein of Kaposi's sarcoma-associated herpesvirus activates the akt signaling pathway Journal of Virology 2004 78 4 1918 1927 (Pubitemid 38176723)
56. Smith P. G., Wang F., Wilkinson K. N., Savage K. J., Klein U., Neuberg D. S., Bollag G., Shipp M. A., Aguiar R. C. T., The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma Blood 2005 105 1 308 316 (Pubitemid 40053098)
57. Shipp M. A., Ross K. N., Tamayo P., Weng A. P., Kutok J. L., Aguiar R. C. T., Gaasenbeek M., Angelo M., Reich M., Pinkus G. S., Ray T. S., Koval M. A., Last K. W., Norton A., Lister T. A., Mesirov J., Neuberg D. S., Lander E. S., Aster J. C., Golub T. R., Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning Nature Medicine 2002 8 1 68 74 (Pubitemid 34101731)
58. Hoyer K. K., French S. W., Turner D. E., Nguyen M. T. N., Renard M., Malone C. S., Knoetig S., Qi C. F., Su T. T., Cheroutre H., Wall R., Rawlings D. J., Morse H. C., Teitell M. A., Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma Proceedings of the National Academy of Sciences of the United States of America 2002 99 22 14392 14397 (Pubitemid 35257682)
59. Lenz G., Wright G. W., Emre N. C. T., Kohlhammer H., Dave S. S., Davis R. E., Carty S., Lam L. T., Shaffer A. L., Xiao W., Powell J., Rosenwald A., Ott G., Muller-Hermelink H. K., Gascoyne R. D., Connors J. M., Campo E., Jaffe E. S., Delabie J., Smeland E. B., Rimsza L. M., Fisher R. I., Weisenburger D. D., Chan W. C., Staudt L. M., Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways Proceedings of the National Academy of Sciences of the United States of America 2008 105 36 13520 13525
60. Navarro A., Be S., Fernndez V., Prieto M., Salaverria I., Jares P., Hartmann E., Mozos A., Lpez-Guillermo A., Villamor N., Colomer D., Puig X., Ott G., Solé F., Serrano S., Rosenwald A., Campo E., Hernndez L., MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in mantle cell lymphomas Cancer Research 2009 69 17 7071 7078
61. Miletic A. V., Anzelon-Mills A. N., Mills D. M., Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases The Journal of Experimental Medicine 2010 207 2407 2420
62. Iwakiri D., Takada K., Phosphatidylinositol 3-kinase is a determinant of responsiveness to B cell antigen receptor-mediated epstein-barr virus activation Journal of Immunology 2004 172 3 1561 1566 (Pubitemid 38116801)
63. Platanias L. C., Map kinase signaling pathways and hematologic malignancies Blood 2003 101 12 4667 4679 (Pubitemid 36857719)
64. Elenitoba-Johnson K. S. J., Jenson S. D., Abbott R. T., Palais R. A., Bohling S. D., Lin Z., Tripp S., Shami P. J., Wang L. Y., Coupland R. W., Buckstein R., Perez-Ordonez B., Perkins S. L., Dube I. D., Lim M. S., Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy Proceedings of the National Academy of Sciences of the United States of America 2003 100 12 7259 7264 (Pubitemid 36706426)
65. Rinaldi A., Kwee I., Taborelli M., Largo C., Uccella S., Martin V., Poretti G., Gaidano G., Calabrese G., Martinelli G., Baldini L., Pruneri G., Capella C., Zucca E., Cotter F. E., Cigudosa J. C., Catapano C. V., Tibiletti M. G., Bertoni F., Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma British Journal of Haematology 2006 132 3 303 316 (Pubitemid 43381537)
66. Huang X., Wullschleger S., Shpiro M., McGuire V. A., Sakamoto K., Woods Y. L., McBurnie W., Fleming S., Alessi D. R., Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice Biochemical Journal 2008 412 2 211 221 (Pubitemid 351758227)
67. Mavrakis K. J., Zhu H., Silva R. L. A., Mills J. R., Teruya-Feldstein J., Lowe S. W., Tam W., Pelletier J., Wendel H. G., Tumorigenic activity and therapeutic inhibition of Rheb GTPase Genes and Development 2008 22 16 2178 2188
68. Sarbassov D. D., Ali S. M., Sengupta S., Sheen J. H., Hsu P. P., Bagley A. F., Markhard A. L., Sabatini D. M., Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB Molecular Cell 2006 22 2 159 168
69. Foster D. A., Toschi A., Targeting mTOR with rapamycin: one dose does not fit all Cell Cycle 2009 8 7 1026 1029
70. Gupta M., Ansell S. M., Novak A. J., Kumar S., Kaufmann S. H., Witzig T. E., Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2 Blood 2009 114 14 2926 2935
71. Wanner K., Hipp S., Oelsner M., Ringshausen I., Bogner C., Peschel C., Decker T., Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab British Journal of Haematology 2006 134 5 475 484 (Pubitemid 44141713)
72. Hipp S., Ringshausen I., Oelsner M., Bogner C., Peschel C., Decker T., Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells Haematologica 2005 90 10 1433 1434 (Pubitemid 41503659)
73. Peng T., Golub T. R., Sabatini D. M., The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation Molecular and Cellular Biology 2002 22 15 5575 5584 (Pubitemid 34755766)
74. LoPiccolo J., Blumenthal G. M., Bernstein W. B., Dennis P. A., Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations Drug Resistance Updates 2008 11 1-2 32 50
75. Bonapace L., Bornhauser B. C., Schmitz M., Cario G., Ziegler U., Niggli F. K., Schfer B. W., Schrappe M., Stanulla M., Bourquin J. P., Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance Journal of Clinical Investigation 2010 120 4 1310 1323
76. Takeuchi H., Kondo Y., Fujiwara K., Kanzawa T., Aoki H., Mills G. B., Kondo S., Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors Cancer Research 2005 65 8 3336 3346 (Pubitemid 40524618)
77. Teachey D. T., Grupp S. A., Brown V. I., Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies British Journal of Haematology 2009 145 5 569 580
78. Yuan R., Kay A., Berg W. J., Lebwohl D., Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy Journal of Hematology and Oncology 2009 2, article 45
79. Tabernero J., Rojo F., Calvo E., Burris H., Judson I., Hazell K., Martinelli E., Cajal S. R., Jones S., Vidal L., Shand N., Macarulla T., Ramos F. J., Dimitrijevic S., Zoellner U., Tang P., Stumm M., Lane H. A., Lebwohl D., Baselga J., Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors Journal of Clinical Oncology 2008 26 10 1603 1610
80. Zeng Z., Sarbassov D. D., Samudio I. J., Yee K. W. L., Munsell M. F., Jackson C. E., Giles F. J., Sabatini D. M., Andreeff M., Konopleva M., Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML Blood 2007 109 8 3509 3512 (Pubitemid 46572543)
81. Wang L., Shi W. Y., Wu Z. Y., Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma Journal of Hematology Oncology 2010 3 30
82. Yazbeck V. Y., Buglio D., Georgakis G. V., Li Y., Iwado E., Romaguera J. E., Kondo S., Younes A., Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma Experimental Hematology 2008 36 4 443 450 (Pubitemid 351384743)
83. Hidalgo M., Buckner J. C., Erlichman C., Pollack M. S., Boni J. P., Dukart G., Marshall B., Speicher L., Moore L., Rowinsky E. K., A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer Clinical Cancer Research 2006 12 19 5755 5763 (Pubitemid 44629606)
84. Raymond E., Alexandre J., Faivre S., Vera K., Materman E., Boni J., Leister C., Korth-Bradley J., Hanauske A., Armand J. P., Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer Journal of Clinical Oncology 2004 22 12 2336 2347 (Pubitemid 41115390)
85. O'Donnell A., Faivre S., Burris H. A. III, Rea D., Papadimitrakopoulou V., Shand N., Lane H. A., Hazell K., Zoellner U., Kovarik J. M., Brock C., Jones S., Raymond E., Judson I., Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors Journal of Clinical Oncology 2008 26 10 1588 1595
86. Tanaka C., O'Reilly T., Kovarik J. M., Shand N., Hazell K., Judson I., Raymond E., Zumstein-Mecker S., Stephan C., Boulay A., Hattenberger M., Thomas G., Lane H. A., Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data Journal of Clinical Oncology 2008 26 10 1596 1602
87. Mita M. M., Mita A. C., Chu Q. S., Rowinsky E. K., Fetterly G. J., Goldston M., Patnaik A., Mathews L., Ricart A. D., Mays T., Knowles H., Rivera V. M., Kreisberg J., Bedrosian C. L., Tolcher A. W., Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies Journal of Clinical Oncology 2008 26 3 361 367 (Pubitemid 351171685)
88. Fetterly G. J., Mita M. M., Britten C. D., Tolcher AW Pharmacokinetics of oral deforolimus (AP23573, MK-8669) Journal of Clinical Oncology 2008 26, Abstract 3509
89. Drakos E., Rassidakis G. Z., Medeiros L. J., Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas Expert Reviews in Molecular Medicine 2008 10 4, article e4 1 21
90. Jaffe E. S., The 2008 WHO classification of lymphomas: implications for clinical practice and translational research Hematology 2009 523 531
91. Romaguera J. E., Mantle cell lymphoma: frontline and salvage therapy Current Hematologic Malignancy Reports 2008 3 4 204 209
92. Haritunians T., Mori A., O'Kelly J., Luong Q. T., Giles F. J., Koeffler H. P., Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma Leukemia 2007 21 2 333 339 (Pubitemid 46158128)
93. Yee K. W. L., Zeng Z., Konopleva M., Verstovsek S., Ravandi F., Ferrajoli A., Thomas D., Wierda W., Apostolidou E., Albitar M., O'Brien S., Andreeff M., Giles F. J., Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies Clinical Cancer Research 2006 12 17 5165 5173 (Pubitemid 44453345)
94. Witzig T. E., Geyer S. M., Ghobrial I., Inwards D. J., Fonseca R., Kurtin P., Ansell S. M., Luyun R., Flynn P. J., Morton R. F., Dakhil S. R., Gross H., Kaufmann S. H., Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma Journal of Clinical Oncology 2005 23 23 5347 5356 (Pubitemid 46206988)
95. Ansell S. M., Inwards D. J., Rowland K. M., Flynn P. J., Morton R. F., Moore D. F., Kaufmann S. H., Ghobrial I., Kurtin P. J., Maurer M., Allmer C., Witzig T. E., Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group Cancer 2008 113 3 508 514
96. Hess G., Herbrecht R., Romaguera J., Verhoef G., Crump M., Gisselbrecht C., Laurell A., Offner F., Strahs A., Berkenblit A., Hanushevsky O., Clancy J., Hewes B., Moore L., Coiffier B., Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma Journal of Clinical Oncology 2009 27 23 3822 3829
97. Yuan R., Kay A., Berg W. J., Lebwohl D., Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy Journal of Hematology and Oncology 2009 2, article 45
98. Ansell S. M., Tang H., Kurtin P. J., Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study The Lancet Oncology 2011 12 361 368
99. Witzig T. E., Reeder C. B., Laplant B. R., A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma Leukemia 2011 25 341 347
100. Rizzieri D. A., Feldman E., Dipersio J. F., Gabrail N., Stock W., Strair R., Rivera V. M., Albitar M., Bedrosian C. L., Giles F. J., A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies Clinical Cancer Research 2008 14 9 2756 2762
101. Armitage J. O., Weisenburger D. D., New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project Journal of Clinical Oncology 1998 16 2780 2795 (Pubitemid 28363044)
102. Uddin S., Hussain A. R., Siraj A. K., Manogaran P. S., Al-Jomah N. A., Moorji A., Atizado V., Al-Dayel F., Belgaumi A., El-Solh H., Ezzat A., Bavi P., Al-Kuraya K. S., Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival Blood 2006 108 13 4178 4186 (Pubitemid 44913290)
103. Smith S. M., van Besien K., Karrison T., Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago phase II consortium Journal of Clinical Oncology 2010 28 4740 4746
104. Fingar D. C., Salama S., Tsou C., Harlow ED., Blenis J., Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E Genes and Development 2002 16 12 1472 1487 (Pubitemid 34686329)
105. Montagne J., Stewart M. J., Stocker H., Hafen E., Kozma S. C., Thomas G., Drosophila S6 kinase: a regulator of cell size Science 1999 285 5436 2126 2129 (Pubitemid 29451430)
106. Stocker H., Hafen E., Genetic control of cell size Current Opinion in Genetics and Development 2000 10 5 529 535
107. Isaacson T. V., Expression of mTOR pathway proteins in malignant lymphoma Laboratory Investigation 2007 246A
108. Georgakis G. V., Li Y., Rassidakis G. Z., Medeiros L. J., Mills G. B., Younes A., Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma British Journal of Haematology 2006 132 4 503 511 (Pubitemid 43381621)
109. Jundt F., Raetzel N., Muller C., A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas Blood 2005 106 1801 1817
110. Johnston P. B., Inwards D. J., Colgan J. P., Laplant B. R., Kabat B. F., Habermann T. M., Micallef I. N., Porrata L. F., Ansell S. M., Reeder C. B., Roy V., Witzig T. E., A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma American Journal of Hematology 2010 85 5 320 324
111. Janes M. R., Fruman D. A., Targeting TOR dependence in cancer Oncotarget 2010 1 69 76
112. Maira S. M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., Brachmann S., Chne P., De Pover A., Schoemaker K., Fabbro D., Gabriel D., Simonen M., Murphy L., Finan P., Sellers W., Garca-Echeverra C., Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Molecular Cancer Therapeutics 2008 7 7 1851 1863
113. Serra V., Markman B., Scaltriti M., Eichhorn P. J. A., Valero V., Guzman M., Botero M. L., Llonch E., Atzori F., Di Cosimo S., Maira M., Garcia-Echeverria C., Parra J. L., Arribas J., Baselga J., NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations Cancer Research 2008 68 19 8022 8030
114. Kojima K., Shimanuki M., Shikami M., Samudio I. J., Ruvolo V., Corn P., Hanaoka N., Konopleva M., Andreeff M., Nakakuma H., The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML Leukemia 2008 22 9 1728 1736
115. Feldman M. E., Apsel B., Uotila A., Loewith R., Knight Z. A., Ruggero D., Shokat K. M., Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 PLoS Biology 2009 7 2, article e38 0371 0383
116. Bhende P. M., Park S. I., Lim M. S., Dittmer D. P., Damania B., The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma Leukemia 2010 24 1781 1784
117. Garca-Martnez J. M., Moran J., Clarke R. G., Gray A., Cosulich S. C., Chresta C. M., Alessi D. R., Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) Biochemical Journal 2009 421 1 29 42
118. Thoreen C. C., Kang S. A., Chang J. W., Liu Q., Zhang J., Gao YI., Reichling L. J., Sim T., Sabatini D. M., Gray N. S., An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 Journal of Biological Chemistry 2009 284 12 8023 8032
119. Yu K., Toral-Barza L., Shi C., Zhang W. G., Lucas J., Shor B., Kim J., Verheijen J., Curran K., Malwitz D. J., Cole D. C., Ellingboe J., Ayral-Kaloustian S., Mansour T. S., Gibbons J. J., Abraham R. T., Nowak P., Zask A., Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin Cancer Research 2009 69 15 6232 6240
120. Janes M. R., Limon J. J., So L., Chen J., Lim R. J., Chavez M. A., Vu C., Lilly M. B., Mallya S., Ong S. T., Konopleva M., Martin M. B., Ren P., Liu YI., Rommel C., Fruman D. A., Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor Nature Medicine 2010 16 2 205 213
121. Chresta C. M., Davies B. R., Hickson I., AZD-8055 is a potent, selective and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity Cancer Research 2009 70 288 298
122. Yu K., Shi C., Toral-Barza L., Lucas J., Shor B., Kim J. E., Zhang W. G., Mahoney R., Gaydos C., Tardio L., Kim S. K., Conant R., Curran K., Kaplan J., Verheijen J., Ayral-Kaloustian S., Mansour T. S., Abraham R. T., Zask A., Gibbons J. J., Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2 Cancer Research 2010 70 2 621 631
123. Dowling R. J., Topisirovic I., Alain T., mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs Science 2010 328 1172 1176
124. Brunn G. J., Williams J., Sabers C., Wiederrecht G., Lawrence J. C. Jr., Abraham R. T., Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002 EMBO Journal 1996 15 19 5256 5267 (Pubitemid 26336209)
125. Chiarini F., Grimaldi C., Ricci F., Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia Cancer Research 2010 70 8097 8107
126. Zhang T. C., Chu H. J., Zhao J. Q., Zhou X. Y., Shi D. R., Study on PI3K inhibitor LY294002 for chemotherapeutic sensitization in diffuse large B cell lymphoma cell lines Zhonghua Xue Ye Xue Za Zhi 2010 31 671 674
127. Hsieh A. C., Costa M., Zollo O., Davis C., Feldman M. E., Testa J. R., Meyuhas O., Shokat K. M., Ruggero D., Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E Cancer Cell 2010 17 3 249 261